The Centre for the Commercialization of Antibodies and Biologics
(CCAB) translates early stage biologics into high-value assets and products.
Our Partners can access a robust portfolio of validated antibodies
and biologics, powered by the University of Toronto's antibody research
and discovery engine: the Toronto Recombinant Antibody Centre (TRAC).
Work with us to access world-class expertise, a state-of-the-art phage
display discovery platform, established antibody libraries and
validated screening technologies.
Technology & Solutions
CCAB reduces the time, cost, and risk associated with antibody development
to create new reagents, diagnostics, and therapeutics.
News & Views
See how CCAB is developing robust pipelines in antibodies and biologics.